Pharma firm GSK has agreed to buy liver disease medicine efimosfermin from US firm Boston Pharmaceuticals, for up to $2 billion in cash. The sum will consist of a $1.2 billion upfront payment and ...

They make full use of their investment universe and allow their stock selection to result in atypical sector weightings. As is the case at the family’s other growth-oriented strategies ...